| First Author | Kwek SS | Year | 2018 |
| Journal | Nat Commun | Volume | 9 |
| Issue | 1 | Pages | 1031 |
| PubMed ID | 29531213 | Mgi Jnum | J:260741 |
| Mgi Id | MGI:6149377 | Doi | 10.1038/s41467-018-03337-2 |
| Citation | Kwek SS, et al. (2018) A systematic approach to the development of a safe live attenuated Zika vaccine. Nat Commun 9(1):1031 |
| abstractText | Zika virus (ZIKV) is a flavivirus that can cause congenital disease and requires development of an effective long-term preventative strategy. A replicative ZIKV vaccine with properties similar to the yellow fever 17D (YF17D) live-attenuated vaccine (LAV) would be advantageous, as a single dose of YF17D produces lifelong immunity. However, a replicative ZIKV vaccine must also be safe from causing persistent organ infections. Here we report an approach to ZIKV LAV development. We identify a ZIKV variant that produces small plaques due to interferon (IFN)-restricted viral propagation and displays attenuated infection of endothelial cells. We show that these properties collectively reduce the risk of organ infections and vertical transmission in a mouse model but remain sufficiently immunogenic to prevent wild-type ZIKV infection. Our findings suggest a strategy for the development of a safe but efficacious ZIKV LAV. |
